What is GenoSpace?
GenoSpace operates as a precision medicine platform tailored for the Sarah Cannon Research Institute (SCRI). The company's core mission is to bridge the divide between clinical research and patient care through advanced technology and specialized services for personalized medicine. Key offerings include sophisticated clinical trial matching systems that leverage clinical-genomic patient data, seamless EMR-to-EDC integration for efficient data transfer, and data-driven study feasibility site selection. By serving community-based oncology practices, GenoSpace plays a crucial role in enhancing patient accruals for clinical trials and furnishing oncologists with real-time, actionable insights to advance innovative cancer therapies.
How much funding has GenoSpace raised?
GenoSpace has raised a total of $5M across 1 funding round:
Private Equity
$5M
Private Equity (2014): $5M with participation from Thomson Reuters
Key Investors in GenoSpace
Thomson Reuters
Thomson Reuters is a global provider of news and information for professional markets. Their involvement suggests a strategic interest in data, analytics, and professional services within the healthcare and research sectors.
What's next for GenoSpace?
With a significant enterprise-level funding round and a major strategic investment, GenoSpace is poised for accelerated growth and market expansion. The company's focus on integrating clinical research with patient care through technology, particularly in oncology, positions it to capitalize on the increasing demand for personalized medicine. Future strategic initiatives will likely involve further development of its platform capabilities, expanding its reach within oncology practices, and potentially forging new partnerships to enhance its data analytics and clinical trial matching services. This backing will be instrumental in scaling operations and solidifying its position as a leader in precision medicine technology.
See full GenoSpace company page
